CENTESSA PHARMACEUTICALS (260) — Working Capital to Net Assets Ratio
CENTESSA PHARMACEUTICALS (260) has a Working Capital to Net Assets ratio of 64.0% as of March 2026. Working capital of €312.11 Million (current assets of €348.68 Million minus current liabilities of €36.57 Million) is measured against net assets of €487.35 Million. A higher ratio indicates strong short-term liquidity financed by the equity base. For the complete balance sheet picture, see CENTESSA PHARMACEUTICALS total assets.
WC/NA Ratio
Working Capital
Current Assets
Current Liabilities
CENTESSA PHARMACEUTICALS Working Capital to Net Assets (2021–2025)
This chart shows how CENTESSA PHARMACEUTICALS's Working Capital to Net Assets ratio has evolved across 5 annual periods from 2021 to 2025. As of March 2026, the ratio stands at 64.0%, reflecting working capital of €312.11 Million against net assets of €487.35 Million EUR. Explore CENTESSA PHARMACEUTICALS (260) cash flow to debt to assess how comfortably operating cash covers total debt obligations.
Annual Working Capital to Net Assets for CENTESSA PHARMACEUTICALS (2021–2025)
The table below presents the year-by-year Working Capital to Net Assets ratio for CENTESSA PHARMACEUTICALS from 2021 to 2025, covering 5 annual filings. Each row shows current assets, current liabilities, working capital, net assets, the ratio, and the change in percentage points compared to the prior year. Explore long-term investment intensity of CENTESSA PHARMACEUTICALS to see how much of total assets are deployed in long-term investments.
| Year | WC/NA Ratio | Working Capital (EUR) | Net Assets | Current Assets | Current Liabilities | Change (pp) |
|---|---|---|---|---|---|---|
| 2025 | 61.7% | €324.94 Million | €526.86 Million | €367.88 Million | €42.94 Million | ▼ -57.5 pp |
| 2024 | 119.1% | €478.41 Million | €401.55 Million | €536.41 Million | €58.00 Million | ▲ +2.4 pp |
| 2023 | 116.7% | €275.71 Million | €236.24 Million | €315.09 Million | €39.38 Million | ▼ -2.1 pp |
| 2022 | 118.8% | €399.41 Million | €336.17 Million | €437.75 Million | €38.34 Million | ▼ -4.1 pp |
| 2021 | 122.9% | €604.14 Million | €491.55 Million | €628.77 Million | €24.64 Million | — |